|
1
|
Wilson JF: Liver cancer on the rise. Ann
Intern Med. 142:1029–1032. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Llovet JM, Ricci S, Mazzaferro V, Hilgard
P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A,
et al: Sorafenib in advanced hepatocellular carcinoma. N Engl J
Med. 359:378–390. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Sherman M: Hepatocellular Carcinoma:
Epidemiology, surveillance, and diagnosis. Semin Liver Dis.
30:3–16. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
El-Serag HB and Rudolph KL: Hepatocellular
carcinoma: Epidemiology and molecular carcinogenesis.
Gastroenterology. 132:2557–2576. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Nordenstedt H, White DL and El-Serag HB:
The changing pattern of epidemiology in hepatocellular carcinoma.
Dig Liver Dis. 42 Suppl 3:S206–S214. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Hynes RO: Integrins: A family of cell
surface receptors. Cell. 48:549–554. 1987. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Giancotti FG and Ruoslahti E: Integrin
signaling. Science. 285:1028–1032. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Hynes RO: Integrins: Bidirectional,
allosteric signaling machines. Cell. 110:673–687. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Patsenker E, Popov Y, Stickel F, Jonczyk
A, Goodman SL and Schuppan D: Inhibition of integrin alphavbeta6 on
cholangiocytes blocks transforming growth factor-beta activation
and retards biliary fibrosis progression. Gastroenterology.
135:660–670. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Breuss JM, Gallo J, DeLisser HM,
Klimanskaya IV, Folkesson HG, Pittet JF, Nishimura SL, Aldape K,
Landers DV, Carpenter W, et al: Expression of the beta 6 integrin
subunit in development, neoplasia and tissue repair suggests a role
in epithelial remodeling. J Cell Sci. 108:2241–2251.
1995.PubMed/NCBI
|
|
11
|
Breuss JM, Gillett N, Lu L, Sheppard D and
Pytela R: Restricted distribution of integrin beta 6 mRNA in
primate epithelial tissues. J Histochem Cytochem. 41:1521–1527.
1993. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Busk M, Pytela R and Sheppard D:
Characterization of the integrin alpha v beta 6 as a
fibronectin-binding protein. J Biol Chem. 267:5790–5796.
1992.PubMed/NCBI
|
|
13
|
Yang GY, Xu KS, Pan ZQ, Zhang ZY, Mi YT,
Wang JS, Chen R and Niu J: Integrin alpha v beta 6 mediates the
potential for colon cancer cells to colonize in and metastasize to
the liver. Cancer Sci. 99:879–887. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Patsenker E, Wilkens L, Banz V,
Osterreicher CH, Weimann R, Eisele S, Keogh A, Stroka D, Zimmermann
A and Stickel F: The alphavbeta6 integrin is a highly specific
immunohistochemical marker for cholangiocarcinoma. J Hepatol.
52:362–369. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Ahmed N, Pansino F, Clyde R, Murthi P,
Quinn MA, Rice GE, Agrez MV, Mok S and Baker MS: Overexpression of
alpha(v)beta6 integrin in serous epithelial ovarian cancer
regulates extracellular matrix degradation via the plasminogen
activation cascade. Carcinogenesis. 23:237–244. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Hecht JL, Dolinski BM, Gardner HA,
Violette SM and Weinreb PH: Overexpression of the alphavbeta6
integrin in endometrial cancer. Appl Immunohistochem Mol Morphol.
16:543–547. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Zhang ZY, Xu KS, Wang JS, Yang GY, Wang W,
Wang JY, Niu WB, Liu EY, Mi YT and Niu J: Integrin alphanvbeta6
acts as a prognostic indicator in gastric carcinoma. Clin Oncol (R
Coll Radiol). 20:61–66. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Azare J, Leslie K, Al-Ahmadie H, Gerald W,
Weinreb PH, Violette SM and Bromberg J: Constitutively activated
Stat3 induces tumorigenesis and enhances cell motility of prostate
epithelial cells through integrin beta 6. Mol Cell Biol.
27:4444–4453. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Marsh D, Dickinson S, Neill GW, Marshall
JF, Hart IR and Thomas GJ: alpha vbeta 6 Integrin promotes the
invasion of morphoeic basal cell carcinoma through stromal
modulation. Cancer Res. 68:3295–3303. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Xu MY, Porte J, Knox AJ, Weinreb PH, Maher
TM, Violette SM, McAnulty RJ, Sheppard D and Jenkins G:
Lysophosphatidic acid induces alphavbeta6 integrin-mediated
TGF-beta activation via the LPA2 receptor and the small G protein G
alpha(q). Am J Pathol. 174:1264–1279. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Geng H, Lan R, Singha PK, Gilchrist A,
Weinreb PH, Violette SM, Weinberg JM, Saikumar P and Venkatachalam
MA: Lysophosphatidic acid increases proximal tubule cell secretion
of profibrotic cytokines PDGF-B and CTGF through LPA2- and
Gαq-mediated Rho and αvβ6 integrin-dependent activation of TGF-β.
Am J Pathol. 181:1236–1249. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Wu K, Ding J, Chen C, Sun W, Ning BF, Wen
W, Huang L, Han T, Yang W, Wang C, et al: Hepatic transforming
growth factor beta gives rise to tumor-initiating cells and
promotes liver cancer development. Hepatology. 56:2255–2267. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Balzarini P, Benetti A, Invernici G,
Cristini S, Zicari S, Caruso A, Gatta LB, Berenzi A, Imberti L,
Zanotti C, et al: Transforming growth factor-beta1 induces
microvascular abnormalities through a down-modulation of neural
cell adhesion molecule in human hepatocellular carcinoma. Lab
Invest. 92:1297–1309. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Kitisin K, Ganesan N, Tang Y, Jogunoori W,
Volpe EA, Kim SS, Katuri V, Kallakury B, Pishvaian M, Albanese C,
et al: Disruption of transforming growth factor-beta signaling
through beta-spectrin ELF leads to hepatocellular cancer through
cyclin D1 activation. Oncogene. 26:7103–7110. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Zhang R, Zhang Z, Pan X, Huang X, Huang Z
and Zhang G: ATX-LPA axis induces expression of OPN in hepatic
cancer cell SMMC7721. Anat Rec (Hoboken). 294:406–411. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Park SY, Jeong KJ, Panupinthu N, Yu S, Lee
J, Han JW, Kim JM, Lee JS, Kang J, Park CG, et al: Lysophosphatidic
acid augments human hepatocellular carcinoma cell invasion through
LPA1 receptor and MMP-9 expression. Oncogene. 30:1351–1359. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Mills GB and Moolenaar WH: The emerging
role of lysophosphatidic acid in cancer. Nat Rev Cancer. 3:582–591.
2003. View
Article : Google Scholar : PubMed/NCBI
|
|
28
|
A new prognostic system for hepatocellular
carcinoma: A retrospective study of 435 patients: The cancer of the
liver Italian program (CLIP) investigators. Hepatology. 28:751–755.
1998. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Knoche K and Kephart D: Cloning blunt-end
PfuDNA Polymerase-generated PCR fragments into pGEM®-T
vector systems. Promega Notes. 71:101999.
|
|
31
|
Kuske L, Mensen A, Müllhaupt B, Negro F,
Semela D, Moradpour D, Male PJ, Heim MH, Malinverni R, Cerny A and
Dufour JF: Swiss Hepatitis C Cohort Study: Characteristics of
patients with chronic hepatitis C who develop hepatocellular
carcinoma. Swiss Med Wkly. 142:w136512012.PubMed/NCBI
|
|
32
|
Tan YJ: Hepatitis B virus infection and
the risk of hepatocellular carcinoma. World J Gastroentero.
17:4853–4857. 2011. View Article : Google Scholar
|
|
33
|
Bates RC, Bellovin DI, Brown C, Maynard E,
Wu B, Kawakatsu H, Sheppard D, Oettgen P and Mercurio AM:
Transcriptional activation of integrin beta6 during the
epithelial-mesenchymal transition defines a novel prognostic
indicator of aggressive colon carcinoma. J Clin Invest.
115:339–347. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Smythe WR, LeBel E, Bavaria JE, Kaiser LR
and Albelda SM: Integrin expression in non-small cell carcinoma of
the lung. Cancer Metastasis Rev. 14:229–239. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Li X, Yang Y, Hu Y, Dang D, Regezi J,
Schmidt BL, Atakilit A, Chen B, Ellis D and Ramos DM:
Alphavbeta6-Fyn signaling promotes oral cancer progression. J Biol
Chem. 278:41646–41653. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Thomas GJ, Nyström ML and Marshall JF:
Alphavbeta6 integrin in wound healing and cancer of the oral
cavity. J Oral Pathol Med. 35:1–10. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Ramos DM, Dang D and Sadler S: The role of
the integrin alpha v beta6 in regulating the epithelial to
mesenchymal transition in oral cancer. Anticancer Res. 29:125–130.
2009.PubMed/NCBI
|
